US Edition
Vaccine for KRAS-Mutated Pancreatic Cancer Stimulates Immune Response
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Vaccine for KRAS-mutated pancreatic cancer stimulates immune response
A vaccine therapy called ELI-002 2P led to anti-cancer immune responses in a Phase 1 trial and showed potential for preventing disease relapses among people with pancreatic cancer related to KRAS gene mutations. “This is an exciting advance for patients with KRAS-driven cancers, particularly pancreatic cancer, where recurrence after standard treatment is almost a given and effective therapies are limited,” Zev Wainberg, MD, professor and researc…
New Cancer Vaccine with Promising Results in Pancreatic and Colorectal Cancer – Deutsches Ärzteblatt
Los Angeles – The final results of the Phase 1 AMPLIFY-201 study, which tested a new immunotherapy for the treatment of KRAS-mutated (mKRAS) pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), indicate good efficacy (Nature Medicine 2025, DOI: 10.1038/s41591-025-03876-4). The substance...
An experimental vaccine against two types of cancer has significantly extended the lifespan of patients in trials, leading scientists to move the project to the next phase and suggest a broad potential application.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
